"""
Question: 1101 

Evidence: In our study, we present data on the HIV DNA level, resistance profile and defective virus pattern in 93 VHIV children from Mali who were treated for a median of 5 years. From August 2013 to April 2014, 97 VHIV HAART-treated children with virological suppression were enrolled; resistance testing was available for 93 children (96%).

Rationale: The paper describes a newly conducted cross-sectional study with prospectively enrolled participants and newly generated measurements (HIV DNA levels, defectivity, resistance genotypes). This indicates it reports original, previously unpublished data rather than a reanalysis or review.

Answer: Yes
"""

"""
Question: 1102 

Evidence: Bulk sequences of the RT and protease genes in DNA were determined on DBSs using the French Agency for HIV Research and Hepatitis (ANRS) sequencing method described at http://www.hivfrenchresistance.org. Consensus sequences were aligned and edited using SmartGene HIV software.

Rationale: The methods explicitly state that viral genes (RT and protease) were sequenced from DNA, confirming that HIV sequences were generated and analyzed.

Answer: Yes
"""

"""
Question: 1103 

Evidence: Bulk sequences of the RT and protease genes in DNA were determined on DBSs using the French Agency for HIV Research and Hepatitis (ANRS) sequencing method. Dried plasma spots (DPSs) were also used to measure ARV levels... Plasma concentrations were determined using liquid chromatography coupled with tandem MS.

Rationale: The study focuses on clinical sampling, genotypic sequencing from DNA, and ARV level measurements. There is no mention of laboratory culture or serial passage of virus in vitro.

Answer: No
"""

"""
Question: 1104 

Evidence: Sequences were interpreted according to the ANRS algorithm (www.hivfrenchresistance.org). Dried plasma spots (DPSs) were also used to measure ARV levels... Plasma concentrations were determined using liquid chromatography coupled with tandem MS.

Rationale: The paper reports genotypic resistance interpretation and drug concentration measurements, not in vitro phenotypic susceptibility testing such as IC50 assays.

Answer: No
"""

"""
Question: 2101 

Evidence: Bulk sequences of the RT and protease genes in DNA were determined... Sequences were interpreted according to the ANRS algorithm. 

Rationale: Although sequencing was performed, the paper does not report any GenBank accession numbers for the sequences; no such identifiers appear in the text.

Answer: No
"""

"""
Question: 2102 

Evidence: Bulk sequences of the RT and protease genes in DNA were determined... Sequences were interpreted according to the ANRS algorithm.

Rationale: The paper contains no GenBank accession numbers for any sequenced clinical isolates, hence none for non-laboratory isolates either.

Answer: No
"""

"""
Question: 2103 

Evidence: Bulk sequences of the RT and protease genes in DNA were determined... Sequences were interpreted according to the ANRS algorithm.

Rationale: No GenBank accession numbers are provided anywhere in the text, so none can be listed.

Answer: NA
"""

"""
Question: 2202 

Evidence: We found 31 patients out of 85 (36%) having at least one resistance mutation related to decreased susceptibility to ART. The most common mutations related to NRTIs were M184I... M184V... followed by T215A/E/F/N/S/Y and K70R.

Rationale: The paper reports aggregate mutation frequencies and proportions, not per-individual mutation lists for each sequenced isolate.

Answer: No
"""

"""
Question: 2301 

Evidence: Participants younger than 20 years old with HIV-1 infection, treated for more than 6 months and with clinical data were included in the study. This cross-sectional study... included ART-treated VHIV children... with sustained virological suppression (plasma HIV-1 RNA ≤50 copies/mL).

Rationale: The study explicitly refers to HIV-1 throughout, indicating that HIV-1 was the species studied.

Answer: HIV-1
"""

"""
Question: 2302 

Evidence: The main HIV-1 subtype was CRF02_AG for 71% of the participants. Subtype distribution... CRF02_AG 65 (71%), A 7 (8%), CRF06_cpx 6 (7%), others 13 (14%) (including 2 CRF02B, 2 CRF02A1, 1 CRF02A1U, 1 CRF02A, 1 CRF02D, 1 CRF09, 1 CRF11, 1 CRF30, 1 D, 1 F2 and 1 H).

Rationale: The paper lists the subtype distribution among participants’ viruses, providing the subtypes studied.

Answer: CRF02_AG (71%), A (8%), CRF06_cpx (7%), and others (including CRF02B, CRF02A1, CRF02A1U, CRF02A, CRF02D, CRF09, CRF11, CRF30, D, F2, H).
"""

"""
Question: 2303 

Evidence: Bulk sequences of the RT and protease genes in DNA were determined on DBSs. We analysed the percentage of defective genomes... (8 in the RT gene and 3 in the protease gene).

Rationale: The targeted genes for sequencing were the reverse transcriptase (RT) and protease regions.

Answer: Reverse transcriptase (RT) and protease (PR) genes (pol gene regions).
"""

"""
Question: 2304 

Evidence: Bulk sequences of the RT and protease genes in DNA were determined on DBSs using the... ANRS sequencing method. Sequences were interpreted according to the ANRS algorithm.

Rationale: RT and protease are components of the HIV-1 pol gene; thus the study reports results of pol sequences.

Answer: Yes
"""

"""
Question: 2401 

Evidence: This cross-sectional study... included ART-treated VHIV children followed at Gabriel Touré Hospital (Bamako, Mali). In our study, we present data... in 93 VHIV children from Mali.

Rationale: The sequences (from the participants) originate from Mali, specifically Bamako.

Answer: Mali (Bamako, Mali)
"""

"""
Question: 2402 

Evidence: From August 2013 to April 2014, 97 VHIV HAART-treated children with virological suppression were enrolled; resistance testing was available for 93 children (96%).

Rationale: The enrollment period indicates when the sequenced samples were obtained.

Answer: 2013–2014 (August 2013 to April 2014)
"""

"""
Question: 2502 

Evidence: Bulk sequences of the RT and protease genes in DNA were determined on DBSs using the French Agency for HIV Research and Hepatitis (ANRS) sequencing method. Consensus sequences were aligned and edited using SmartGene HIV software.

Rationale: The ANRS “bulk” population sequencing method corresponds to Sanger sequencing; no NGS platform is mentioned. The use of consensus sequences further supports Sanger population sequencing.

Answer: Yes
"""

"""
Question: 2503 

Evidence: Bulk sequences of the RT and protease genes in DNA were determined... using the ANRS sequencing method. Consensus sequences were aligned and edited using SmartGene HIV software.

Rationale: There is no mention of any next-generation sequencing platform or methods; the description is consistent with Sanger bulk sequencing.

Answer: No
"""

"""
Question: 2504 

Evidence: Bulk sequences of the RT and protease genes in DNA were determined on DBSs. Consensus sequences were aligned and edited...

Rationale: The study used bulk population sequencing from DNA extracted from dried blood spots; there is no indication that samples were cloned prior to sequencing.

Answer: No
"""

"""
Question: 2505 

Evidence: Bulk sequences of the RT and protease genes in DNA were determined on DBSs. Consensus sequences were aligned and edited...

Rationale: “Bulk” population sequencing is distinct from single-genome sequencing; there is no mention of SGS.

Answer: No
"""

"""
Question: 2506 

Evidence: Bulk sequences of the RT and protease genes in DNA were determined on DBSs. 

Rationale: No molecular cloning procedures are described; sequencing was performed directly on bulk DNA from clinical samples.

Answer: No
"""

"""
Question: 2601 

Evidence: Bulk sequences of the RT and protease genes in DNA were determined on DBSs. HIV RNA resistance determination is technically impossible when the viral load is suppressed.

Rationale: Sequencing was performed on DNA from dried blood spots, not on plasma RNA. The authors also note RNA resistance testing was not feasible due to suppressed viremia.

Answer: No
"""

"""
Question: 2602 

Evidence: In order to evaluate the size of the HIV-1 viral reservoir, total DNA was extracted from whole blood derived from dried blood spots (DBSs). Bulk sequences of the RT and protease genes in DNA were determined on DBSs.

Rationale: The sequencing source was whole blood DBS-derived DNA, not isolated PBMCs.

Answer: No
"""

"""
Question: 2603 

Evidence: Bulk sequences of the RT and protease genes in DNA were determined on DBSs. HIV RNA resistance determination is technically impossible when the viral load is suppressed.

Rationale: Since no plasma RNA sequencing was performed, the number of plasma virus sequences is zero.

Answer: 0
"""

"""
Question: 2604 

Evidence: In order to evaluate the size of the HIV-1 viral reservoir, total DNA was extracted from whole blood derived from dried blood spots (DBSs). Bulk sequences of the RT and protease genes in DNA were determined on DBSs.

Rationale: Sequencing was not performed on PBMCs; hence the count for PBMC virus sequencing is zero.

Answer: 0
"""

"""
Question: 2605 

Evidence: This cross-sectional study... included ART-treated VHIV children... with sustained virological suppression (plasma HIV-1 RNA ≤50 copies/mL) for at least 6 months. 

Rationale: Participants had suppressed plasma viremia, indicating sequences were not obtained from individuals with active HIV replication.

Answer: No
"""

"""
Question: 2606 

Evidence: In order to evaluate the size of the HIV-1 viral reservoir, total DNA was extracted from whole blood derived from dried blood spots (DBSs)... The cell-associated HIV-1 DNA level was quantified... Bulk sequences of the RT and protease genes in DNA were determined on DBSs.

Rationale: Sequencing targeted cell-associated (proviral) HIV DNA, i.e., the proviral DNA reservoir.

Answer: Yes
"""

"""
Question: 2701 

Evidence: This cross-sectional study... included ART-treated VHIV children followed at Gabriel Touré Hospital (Bamako, Mali). Participants younger than 20 years old with HIV-1 infection... were included in the study.

Rationale: The study explicitly involved children and adolescents (vertically infected).

Answer: Yes
"""

"""
Question: 2702 

Evidence: This cross-sectional study, conducted within a prospective cohort, included ART-treated VHIV children... The study was approved by the National AIDS programme... and the Malian Institutional Ethics Committee...

Rationale: The design is a cross-sectional study within a cohort, not a clinical trial; no randomization/intervention trial is described.

Answer: No
"""

"""
Question: 2703 

Evidence: This cross-sectional study, conducted within a prospective cohort, included ART-treated VHIV children... 

Rationale: Because it was not a clinical trial, it follows that not all individuals were in a clinical trial.

Answer: No
"""

"""
Question: 3101 

Evidence: From August 2013 to April 2014, 97 VHIV HAART-treated children with virological suppression were enrolled; resistance testing was available for 93 children (96%). Resistance testing in HIV DNA was performed in 97 participants, samples were not amplifiable for 2... and 4... had complete PCR failure because DNA was undetectable (not included).

Rationale: The clearest reported count for those with available resistance testing is 93, consistent with PCR failures described.

Answer: 93
"""

"""
Question: 3102 

Evidence: From August 2013 to April 2014, 97 VHIV HAART-treated children... were enrolled; resistance testing was available for 93 children (96%). Resistance testing in HIV DNA was performed in 97 participants, samples were not amplifiable for 2... and 4... had complete PCR failure... (not included).

Rationale: Not all enrolled individuals had successful sequencing/resistance testing; several samples failed, leaving fewer than the total.

Answer: No
"""

"""
Question: 4101 

Evidence: This cross-sectional study... included ART-treated VHIV children... The frequencies of ARV exposure were 100% for NRTIs... 92% for NNRTIs... and 45% for PIs...

Rationale: All participants were ART-experienced; there were no ART-naive individuals.

Answer: No
"""

"""
Question: 4102 

Evidence: This cross-sectional study... included ART-treated VHIV children... The frequencies of ARV exposure were 100% for NRTIs... 92% for NNRTIs... and 45% for PIs...

Rationale: The sequences originate from ART-experienced individuals.

Answer: Yes
"""

"""
Question: 4103 

Evidence: This cross-sectional study... included ART-treated VHIV children... The frequencies of ARV exposure were 100% for NRTIs... 92% for NNRTIs... and 45% for PIs...

Rationale: Only ART-experienced individuals were included; no ART-naive participants were sequenced.

Answer: No
"""

"""
Question: 4104 

Evidence: This cross-sectional study... included ART-treated VHIV children... The frequencies of ARV exposure were 100% for NRTIs... 92% for NNRTIs...

Rationale: Since all participants were ART-experienced, zero samples came from ART-naive individuals.

Answer: 0
"""

"""
Question: 4105 

Evidence: As shown in Table 1, 57% of the children were on first-line treatment and the others at least on second-line treatment. We were unable to differentiate the contribution of NNRTI exposure versus transmitted resistance because it was the first resistance genotypic test performed.

Rationale: The paper provides aggregate regimen information rather than complete, detailed ART histories for each individual, and explicitly notes limitations in distinguishing prior exposures versus transmitted resistance.

Answer: No
"""

"""
Question: 4201 

Evidence: We were unable to differentiate the contribution of NNRTI exposure versus transmitted resistance because it was the first resistance genotypic test performed. 

Rationale: The authors explicitly state they could not distinguish transmitted resistance; hence no prevalence of transmitted resistance is reported.

Answer: No
"""

"""
Question: 4202 

Evidence: Participants younger than 20 years old with HIV-1 infection, treated for more than 6 months... were included in the study. We were unable to differentiate the contribution of NNRTI exposure versus transmitted resistance...

Rationale: The study did not analyze pretreatment resistance; all participants were treatment-experienced and already suppressed.

Answer: No
"""

"""
Question: 4301 

Evidence: The frequencies of ARV exposure were 100% for NRTIs (100% for emtricitabine/lamivudine and 84% for zidovudine), 92% for NNRTIs (87% for nevirapine and 19% for efavirenz) and 45% for PIs (39% for lopinavir and 10% for nelfinavir). 

Rationale: These sentences list the antiretroviral drug classes received: NRTIs, NNRTIs, and PIs.

Answer: NRTIs, NNRTIs, and PIs
"""

"""
Question: 4302 

Evidence: The frequencies of ARV exposure were 100% for NRTIs... 92% for NNRTIs... and 45% for PIs... Since 2018, the recommended first-line regimen has been composed of two NRTIs and one integrase inhibitor... or... one PI...

Rationale: The cohort exposure data list only NRTIs, NNRTIs, and PIs; integrase inhibitor use is discussed only as guideline context, not as received by participants.

Answer: No
"""

"""
Question: 4303 

Evidence: The frequencies of ARV exposure were... 45% for PIs (39% for lopinavir and 10% for nelfinavir). 

Rationale: The study reports that many participants received PIs and specifies which ones.

Answer: Yes
"""

"""
Question: 4304 

Evidence: As shown in Table 1, 57% of the children were on first-line treatment and the others at least on second-line treatment. The first- and second-line regimens listed include multiple different combinations (e.g., ZDV+3TC+NVP; ABC+3TC+LPV; etc.).

Rationale: The cohort received a variety of ART regimens; therefore not all individuals received the same ART.

Answer: No
"""

"""
Question: 4305 

Evidence: The frequencies of ARV exposure were 100% for NRTIs, 92% for NNRTIs and 45% for PIs. No integrase inhibitors are listed among the regimens received, and the enrollment period was August 2013 to April 2014 (before the 2018 guideline recommending dolutegravir).

Rationale: Regimens listed contain no INSTIs, indicating participants were INSTI-naive.

Answer: Yes
"""

"""
Question: 4403 

Evidence: As shown in Table 1, 57% of the children were on first-line treatment and the others at least on second-line treatment.

Rationale: Those on second-line (43% of 93 = 40 individuals) have had more than one ART regimen.

Answer: 40
"""

"""
Question: 4404 

Evidence: As shown in Table 1, 57% of the children were on first-line treatment and the others at least on second-line treatment.

Rationale: The paper distinguishes only first- versus at least second-line and does not quantify those with more than two regimens; thus the number cannot be determined.

Answer: NA
"""

"""
Question: 4405 

Evidence: As shown in Table 1, 57% of the children were on first-line treatment and the others at least on second-line treatment.

Rationale: Because some were on first-line and others on at least second-line, individuals did not all receive the same number of regimens.

Answer: No
"""

"""
Question: 4406 

Evidence: As shown in Table 1, 57% of the children were on first-line treatment and the others at least on second-line treatment.

Rationale: Since 43% were on at least second-line therapy, not all individuals received only one regimen.

Answer: No
"""

"""
Question: 4501 

Evidence: The frequencies of ARV exposure were 100% for NRTIs... 92% for NNRTIs... and 45% for PIs (39% for lopinavir and 10% for nelfinavir). The recommended first-line regimen including dolutegravir is mentioned for 2018 guidelines, but the cohort was enrolled from August 2013 to April 2014.

Rationale: No participant regimens include dolutegravir and the study predates its routine use in this setting.

Answer: 0
"""

"""
Question: 4502 

Evidence: The frequencies of ARV exposure were... 45% for PIs (39% for lopinavir and 10% for nelfinavir). 

Rationale: Only lopinavir and nelfinavir are reported PI exposures; darunavir is not reported as received by participants.

Answer: 0
"""

"""
Question: 5101 

Evidence: We found 31 patients out of 85 (36%) having at least one resistance mutation related to decreased susceptibility to ART. 

Rationale: The paper provides the count of individuals with one or more resistance mutations.

Answer: 31
"""

"""
Question: 5102 

Evidence: Bulk sequences of the RT and protease genes in DNA were determined on DBSs. The most common mutations related to NNRTIs... NRTIs... Major mutations related to PI resistance...

Rationale: Integrase was not sequenced and no INSTI mutations were assessed or reported.

Answer: 0
"""

"""
Question: 5103 

Evidence: None of the children was exposed to tenofovir. According to the genotypic analysis... we detected resistance... Eight out of the 91 children (9%) had viruses resistant to zidovudine or stavudine; 4/91 to didanosine; 26/91 to lamivudine and 26/91 to abacavir.

Rationale: The paper reports resistance counts for several NRTIs but does not report counts specifically for tenofovir; hence the number cannot be determined from the text.

Answer: NA
"""

"""
Question: 5104 

Evidence: Bulk sequences of the RT and protease genes in DNA were determined on DBSs. Sequences were interpreted according to the ANRS algorithm.

Rationale: The study did not sequence the integrase gene and does not report any INSTI-resistance mutations.

Answer: NA
"""

"""
Question: 6101 

Evidence: Sequences were interpreted according to the ANRS algorithm (genotypic). Dried plasma spots were used to measure ARV levels... Plasma concentrations were determined using liquid chromatography coupled with tandem MS.

Rationale: No phenotypic susceptibility assay was performed or described; only genotypic resistance and drug level measurements are reported.

Answer: NA
"""

"""
Question: 6102 

Evidence: Sequences were interpreted according to the ANRS algorithm. Plasma concentrations were determined using liquid chromatography coupled with tandem MS.

Rationale: There are no reported IC50/IC90 values; only genotypic results and pharmacokinetic measurements are presented.

Answer: No
"""

"""
Question: 6103 

Evidence: Sequences were interpreted according to the ANRS algorithm. Plasma concentrations were determined using liquid chromatography coupled with tandem MS.

Rationale: The paper does not report IC50 fold change values.

Answer: No
"""

"""
Question: 6104 

Evidence: Sequences were interpreted according to the ANRS algorithm. 

Rationale: No phenotypic susceptibility assay is described; only genotypic interpretation is performed.

Answer: NA
"""

"""
Question: 6105 

Evidence: We analysed the percentage of defective genomes... We showed a high prevalence of HIV-1 resistance in DNA... Dried plasma spots were also used to measure ARV levels...

Rationale: The paper does not report replication capacity measurements.

Answer: No
"""

"""
Question: 6106 

Evidence: Sequences were interpreted according to the ANRS algorithm. Plasma concentrations were determined using liquid chromatography coupled with tandem MS.

Rationale: No phenotypic susceptibility testing was conducted; therefore, no drugs were tested phenotypically.

Answer: NA
"""

"""
Question: 7101 

Evidence: Bulk sequences of the RT and protease genes in DNA were determined on DBSs. This cross-sectional study... included ART-treated VHIV children...

Rationale: All sequences derive from clinical samples without laboratory-engineered site-directed mutants.

Answer: No
"""

"""
Question: 7102 

Evidence: Bulk sequences of the RT and protease genes in DNA were determined on DBSs. This cross-sectional study... included ART-treated VHIV children...

Rationale: The study did not perform in vitro passage; it analyzed clinical specimens only.

Answer: No
"""